To determine if the TCF1high CD8 + T cells resulting from PKM2 deficiency respond to PD-1 inhibition to exert anti-tumor effects, we tested a combination of anti-PD-1 and PKM2 loss in CD8 + T cells in the HKP1-ova-GFP mouse model. Here, CD8A is linked to neoplasm.